Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Investing Activities (2016 - 2025)

China Pharma Holdings' Cash from Investing Activities history spans 16 years, with the latest figure at -$5767.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 97.89% year-over-year to -$5767.0; the TTM value through Dec 2025 reached -$137251.0, up 59.1%, while the annual FY2025 figure was -$137251.0, 52.95% up from the prior year.
  • Cash from Investing Activities reached -$5767.0 in Q4 2025 per CPHI's latest filing, up from -$40598.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $55964.0 in Q1 2023 to a low of -$415977.0 in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$77337.3, with a median of -$8488.5 recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 4123.29% in 2023, then plummeted 5927.21% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$7056.0 in 2021, then skyrocketed by 486.45% to $27268.0 in 2022, then plummeted by 116.6% to -$4527.0 in 2023, then tumbled by 5927.21% to -$272852.0 in 2024, then surged by 97.89% to -$5767.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Cash from Investing Activities are -$5767.0 (Q4 2025), -$40598.0 (Q3 2025), and -$9921.0 (Q2 2025).